Litigation Details for Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-03-27 |
Court | District Court, D. Delaware | Date Terminated | 2018-09-21 |
Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | Plaintiff | Referred To | |
Patents | 7,964,580; 8,334,270; 8,580,765; 8,618,076; 8,633,309; 8,889,159; 9,085,573; 9,284,342; 9,549,941 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc.
Details for Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-03-27 | 1 | expiration of U.S. Patent Nos. 7,964,580 (the “’580 patent”); 8,334,270 (the “’270 patent”); 8,580,765 (the…Office duly and legally issued U.S. Patent No. 7,964,580 (the “’580 patent”), titled “Nucleoside Phosphoramidate…identifies the following patents as covering Sovaldi®: U.S. Patent Nos. 7,964,580; 8,334,270; 8,580,765;…ANDA Product before the expiration of U.S. Patent Nos. 7,964,580; 8,334,270; 8,580,765; 9,085,573; 8,633,309…that Teva has infringed the claims of U.S. Patent Nos. 7,964,580; 8,334,270; 8,580,765; 9,085,573; 8,633,309 | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |